STOCK TITAN

Cronos Group Stock Price, News & Analysis

CRON Nasdaq

Welcome to our dedicated page for Cronos Group news (Ticker: CRON), a resource for investors and traders seeking the latest updates and insights on Cronos Group stock.

Cronos Group Inc. (CRON) generates frequent news as a cannabinoid-focused company active in medical and adult-use cannabis markets across Canada, Israel and multiple international regions. Company updates often highlight brand performance, international expansion, product launches and financial results, offering investors and industry observers insight into how Cronos executes its global cannabis strategy.

News coverage for Cronos commonly includes quarterly earnings releases, where the company reports net revenue, gross profit, adjusted EBITDA and commentary on business performance by geography and brand. These releases also describe developments such as the consolidation and expansion of cultivation operations at Cronos Growing Company Inc. (Cronos GrowCo) and the company’s cash and short-term investment position.

Another major category of Cronos news involves brand and product announcements. Recent press releases describe new SOURZ by Spinach® Fully Blasted multipack gummies, seasonal Spinach® Caramel Green Apple gummies and vapes, and Lord Jones® Live Resin Fusions™ pre-rolls in Canada. These updates show how Cronos uses its Spinach® and Lord Jones® brands to introduce new formats and flavor profiles in the Canadian adult-use market.

Cronos also issues news on its international footprint and strategic transactions. Examples include the expansion of PEACE NATURALS® medical cannabis distribution in Switzerland through a partnership with Dascoli Pharma AG, and a definitive agreement for a Cronos subsidiary to acquire CanAdelaar B.V., a licensed producer in the Netherlands’ adult-use cannabis pilot program. In addition, the company has announced a junior secured convertible loan investment in High Tide Inc., a cannabis retailer, outlining the terms of that financing.

Investors and followers of CRON can use this news feed to review earnings announcements, track new product introductions under Spinach®, PEACE NATURALS® and Lord Jones®, and monitor strategic moves such as international partnerships, acquisitions and capital investments.

Rhea-AI Summary

Cronos Group Inc. (NASDAQ: CRON) will host its 2021 Second Quarter Earnings Conference Call on August 6, 2021, at 8:30 a.m. EDT. Senior management will review the Company’s financial results and address questions from investors. A live audio webcast will be accessible on the Company’s website, and the call will be archived for later listening. Cronos Group focuses on developing cannabinoid products globally, with brands like PEACE NATURALS™, COVE™, and Spinach™ in its portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
conferences earnings
-
Rhea-AI Summary

Cronos Group held its Annual Meeting of Shareholders on June 25, 2021, with 75.35% of outstanding shares represented. All proposed directors were elected, receiving over 94.38% of votes. Notable votes included Kendrick Ashton, Jr. with 99.61% support and Jody Begley with 94.38%. An advisory resolution on executive compensation was approved by 93.64% of votes. KPMG LLP was re-appointed as independent auditors. For complete voting results, refer to the Company’s filings on SEDAR and EDGAR.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
none
-
Rhea-AI Summary

Cronos Group has entered into a strategic agreement to purchase an option for a 10.5% stake in PharmaCann for approximately $110.4 million. This investment positions Cronos to benefit from the expanding U.S. cannabis market, particularly in states where PharmaCann operates, which includes six limited-license states. Both companies plan to collaborate on product distribution and governance rights following the option's exercise, contingent on regulatory approvals and U.S. federal cannabis legalization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
none
Rhea-AI Summary

Cronos Group (NASDAQ: CRON) and Ginkgo Bioworks have amended their collaboration agreement to expedite the commercialization of cultured cannabinoids. The new terms allow Cronos to market products using cultured cannabinoids before meeting previously defined productivity targets, enhancing their market position in Canada. Following the receipt of necessary licenses, Cronos has commenced commercial production of CBG. The agreement maintains the original share issuance structure tied to productivity milestones, with the potential to produce rare cannabinoids reliably and economically.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
none
-
Rhea-AI Summary

Cronos Group, a global cannabinoid company, announced that Mike Gorenstein, Executive Chairman, will speak at Canaccord Genuity’s 5th Annual Global Cannabis Conference on May 11, 2021, at 2:30 p.m. EDT. Participants can access the live webcast at thecronosgroup.com. Following the event, a replay will be available. Cronos is focused on developing disruptive intellectual property and building a strong brand portfolio with products like PEACE NATURALS, COVE, and Spinach.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.2%
Tags
conferences
-
Rhea-AI Summary

Cronos Group (NASDAQ: CRON) has unveiled a comprehensive Marketing Code aimed at promoting responsible marketing practices in the cannabis industry. This initiative emphasizes that marketing should not target individuals below the legal consumption age. The code will govern all Cronos marketing activities worldwide and is intended to engage both industry peers and policymakers. Key principles include adult-targeted advertising, responsible consumption messaging, and transparency in claims. Cronos Group's leadership believes this initiative is vital for fostering trust in the evolving cannabis market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.2%
Tags
none
Rhea-AI Summary

Cronos Group recently announced its Q1 2021 results, reporting consolidated net revenue of $12.6 million, a 50% increase from Q1 2020, driven by growth in the Canadian and Israeli markets. Despite increased sales, the company experienced a gross loss of $2.96 million, improved from $6.48 million a year prior. The newly acquired processing license for cannabinoid biosynthesis is a significant achievement, supporting innovative product development. However, adjusted EBITDA loss slightly increased to $37.1 million, reflecting higher marketing and R&D costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
-
Rhea-AI Summary

Cronos Group Inc. (NASDAQ: CRON) will hold its 2021 Annual Meeting of Shareholders on June 25, 2021, at 11:00 a.m. EDT in a virtual format due to COVID-19 health concerns. Shareholders and proxyholders can participate online, ask questions, and vote. The proxy statement with meeting details is available on the Company’s website. A replay of the meeting will be accessible within 24 hours post-event. Cronos Group, a global cannabinoid company, focuses on advancing cannabis research and product development, aiming to enhance consumer experience through a diverse brand portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
none
-
Rhea-AI Summary

Cronos Group Inc. (NASDAQ: CRON) will host its 2021 First Quarter Earnings Conference Call on May 7, 2021, at 8:30 a.m. EDT. The call will allow management to discuss the company's financial results and address questions from investors. A live audio webcast will be available on the company's website, with an archived replay afterward. Cronos Group focuses on cannabinoid production and is building a diverse brand portfolio, including various wellness and hemp-derived CBD brands.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
conferences earnings
Rhea-AI Summary

Cronos Group announces the launch of its first brand campaign for the Lord Jones™ brand, named “A Higher Order”, aimed at expanding its market presence in the U.S. This campaign includes out-of-home advertising and television spots featuring new creative assets, which showcase the brand's premium CBD products. The initiative reflects the brand's evolution and commitment to elevating consumer wellness experiences.

The campaign will be celebrated with a live-streamed “Sunday Bath Session” on May 2, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.8%
Tags
none

FAQ

What is the current stock price of Cronos Group (CRON)?

The current stock price of Cronos Group (CRON) is $2.6 as of March 3, 2026.

What is the market cap of Cronos Group (CRON)?

The market cap of Cronos Group (CRON) is approximately 1.0B.

CRON Rankings

CRON Stock Data

1.01B
193.62M
Drug Manufacturers - Specialty & Generic
Medicinal Chemicals & Botanical Products
Link
Canada
STAYNER

CRON RSS Feed